{"analyses":[{"ciLowerLimit":"0.778","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.147","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.25885","estimateComment":"The control group is considered the reference group.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.35","paramType":"Hazard Ratio (HR)","paramValue":"1.293","statisticalComment":"Log-rank test to compare survival distributions between the control group and treatment group.","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"groups":[{"description":"Received antimicrobial therapy alone.","id":"OG000","title":"Control Arm"},{"description":"Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.","id":"OG001","title":"Granulocyte Arm"}],"paramType":"NUMBER","populationDescription":"All randomized subjects.","reportingStatus":"POSTED","timeFrame":"Measured at Month 3","title":"Long-term Survival","type":"SECONDARY","unitOfMeasure":"participants"}